WuXi AppTec Co., Ltd. (HKG:2359)

Market Cap	344.28B
Revenue (ttm)	45.91B
Net Income (ttm)	15.09B
Shares Out	n/a
EPS (ttm)	4.37
PE Ratio	22.81
Forward PE	22.67
Dividend	1.82 (1.66%)
Ex-Dividend Date	Sep 8, 2025

Volume	7,309,714
Average Volume	8,607,848
Open	113.50
Previous Close	111.80
Day's Range	108.60 - 115.50
52-Week Range	37.10 - 120.30
Beta	0.75
RSI	52.11
Earnings Date	Oct 27, 2025

About WuXi AppTec

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People’s Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecula...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2000
• Employees: 39,414
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2359

Financial Performance

In 2024, WuXi AppTec's revenue was 37.92 billion, a decrease of -1.97% compared to the previous year's 38.68 billion. Earnings were 9.45 billion, a decrease of -1.63%.

Financial numbers in CNY